Cited by 406Cancer Immunotherapy and BiomarkersTGF-β signaling in diseasesImmunotherapy and Immune Responses

The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

Open access

Strauss, Julius, Heery, Christopher R., Schlom, Jeffrey, Madan, Ravi A., Cao, Liang, Kang, Zhigang, Lamping, Elizabeth, Marté, Jennifer L., Donahue, Renee N., Grenga, Italia, Cordes, Lisa, Christensen, Olaf, Mahnke, Lisa, Helwig, Christoph, Gulley, James L.·2018·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-17-2653PMC PMC7985967

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Purpose: M7824 (MSB0011359C) is an innovative first-in-class bifunctional fusion protein composed of a mAb against programmed death ligand 1 (PD-L1) fused to a TGFβ “trap.” Experimental Design: In the 3+3 dose-escalation component of this phase I study (NCT02517398), eligible patients with advanced solid tumors received M7824 at 1, 3, 10, or 20 mg/kg once every 2 weeks until confirmed progression, unacceptable toxicity, or trial withdrawal; in addition, a cohort received an initial 0.3 mg/kg dose to evaluate pharmacokinetics/pharmacodynamics, followed by 10 mg/kg dosing. The primary objective is to determine the safety and maximum tolerated dose (MTD); secondary objectives include pharmacokinetics, immunogenicity, and best overall response. Results: Nineteen heavily pretreated patients with ECOG 0–1 have received M7824. Grade ≥3 treatment-related adverse events occurred in four patients (skin infection secondary to localized bullous pemphigoid, asymptomatic lipase increase, colitis with associated anemia, and gastroparesis with hypokalemia). The MTD was not reached. M7824 saturated peripheral PD-L1 and sequestered any released plasma TGFβ1, -β2, and -β3 throughout the dosing period at >1 mg/kg. There were signs of efficacy across all dose levels, including one ongoing confirmed complete response (cervical cancer), two durable confirmed partial responses (PR; pancreatic cancer; anal cancer), one near-PR (cervical cancer), and two cases of prolonged stable disease in patients with growing disease at study entry (pancreatic cancer; carcinoid). Conclusions: M7824 has a manageable safety profile in patients with heavily pretreated advanced solid tumors. Early signs of efficacy are encouraging, and multiple expansion cohorts are ongoing in a range of tumors. Clin Cancer Res; 24(6); 1287–95. ©2018 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-2653

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,725

Show all 35 references

Sorted by citations

Items 201–300 of 406

Radiolabelling and preclinical characterization of 89Zr-Df-radiolabelled bispecific anti-PD-L1/TGF-βRII fusion protein bintrafusp alfa
Burvenich, I. J. G., Goh, Y. W., Guo, N. Y., Gan, H. K., Rigopoulos, A., Cao, D., Liu, Z., Ackermann, U., Wichmann, C. W., McDonald, A. F., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05251-0 · Cited by 27
Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance
Heumann, T. R., & Azad, N. S. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09981-3 · Cited by 26
Advancements and challenges in immunocytokines: A new arsenal against cancer
Shi, W., Liu, N., & Lu, H. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.07.024 · Cited by 25
Therapeutic efficacy and mechanism of CD73-TGFβ dual-blockade in a mouse model of triple-negative breast cancer
Xing, Y., Ren, Z., Jin, R., Liu, L., Pei, J., & Yu, K. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00840-z · Cited by 25
RETRACTED: Coagulation and inflammation in cancer: Limitations and prospects for treatment
Singh, A. K., & Malviya, R. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188727 · Cited by 26
Retracted
Genetically Engineered Hematopoietic Stem Cells Deliver TGF‐β Inhibitor to Enhance Bone Metastases Immunotherapy
Wang, B., Bai, J., Tian, B., Chen, H., Yang, Q., Chen, Y., Xu, J., Zhang, Y., Dai, H., Ma, Q., et al. (2022) · Advanced Science · doi:10.1002/advs.202201451 · Cited by 25
The TGF-β superfamily as potential therapeutic targets in pancreatic cancer
Tindall, R. R., Bailey, J. M., Cao, Y., & Ko, T. C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1362247 · Cited by 26
Immune-Inhibitory Gene Expression is Positively Correlated with Overall Immune Activity and Predicts Increased Survival Probability of Cervical and Head and Neck Cancer Patients
Budhwani, M., Turrell, G., Yu, M., Frazer, I. H., Mehdi, A. M., & Chandra, J. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.622643 · Cited by 25
Immune dynamics shaping pre-metastatic and metastatic niches in liver metastases: from molecular mechanisms to therapeutic strategies
Zhu, C., Liao, J.-Y., Liu, Y., Chen, Z., Chang, R.-Z., Chen, X., Zhang, B., & Liang, J.-N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02171-z · Cited by 28
Inhibition of TGFβ1 and TGFβ3 promotes hematopoiesis in Fanconi anemia
Rodríguez, A., Yang, C., Furutani, E., Teresa, B. G., Velázquez, M., Filiatrault, J., Sambel, L. A., Phan, T., Flores-Guzmán, P., Sánchez, S., et al. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.11.002 · Cited by 24
Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009
Pellom, S. T., Rumfield, C. S., Morillon, Y. M., Roller, N., Poppe, L. K., Brough, D. E., Sabzevari, H., Schlom, J., & Jochéms, C. (2021) · JCI Insight · doi:10.1172/jci.insight.141912 · Cited by 24
Self-citation
Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
Tsai, Y.-T., Strauss, J., Toney, N. J., Jochéms, C., Venzon, D. J., Gulley, J. L., Schlom, J., & Donahue, R. N. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004601 · Cited by 24
Self-citation
Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1
Vugmeyster, Y., Grišić, A., Wilkins, J. J., Loos, A. H., Hallwachs, R., Osada, M., Venkatakrishnan, K., & Khandelwal, A. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04468-6 · Cited by 27
Metabolic hallmarks of natural killer cells in the tumor microenvironment and implications in cancer immunotherapy
Yang, Y., Chen, L., Zheng, B., & Zhou, S. (2022) · Oncogene · doi:10.1038/s41388-022-02562-w · Cited by 27
Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer
Gatti-Mays, M. E., Gameiro, S. R., Ozawa, Y., Knudson, K. M., Hicks, K. C., Palena, C., Cordes, L. M., Steinberg, S. M., Francis, D. C., Karzai, F. H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.581801 · Cited by 23
Self-citation
Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer
Suzuki, S., Haratani, K., Hayashi, H., Chiba, Y., Tanizaki, J., Kato, R., Mitani, S., Kawanaka, Y., Kurosaki, T., Hasegawa, Y., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.11.011 · Cited by 23
Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions
López‐Campos, F., Gajate, P., Romero-Laorden, N., Zafra, J., Juan, M., Polo, S. H., Conde-Moreno, A. J., & Couñago, F. (2022) · Biomedicines · doi:10.3390/biomedicines10030537 · Cited by 24
The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF‐β receptor plus dual checkpoint inhibition maintains antitumor immune cells
Rana, M., Kansal, R. G., Chaib, M., Teng, B., Morrrison, M., Hayes, D. N., Stanfill, A. G., Shibata, D., Carson, J. A., Makowski, L., et al. (2022) · Molecular Carcinogenesis · doi:10.1002/mc.23401 · Cited by 24
Therapeutic bispecific antibodies against intracellular tumor antigens
Xu, G., Luo, Y., Wang, H., Wang, Y., Liu, B., & Wei, J. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215699 · Cited by 23
Targeting PARP for the optimal immunotherapy efficiency in gynecologic malignancies
Li, T., Wang, X., Qin, S., Chen, B., Yi, M., & Zhou, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114712 · Cited by 24
Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis
Alifu, M., Tao, M., Chen, X., Chen, J., Tang, K., & Tang, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1146905 · Cited by 23
Research progress in tumor targeted immunotherapy
Fang, Y., Yu, A., Ye, L., & Zhai, G. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1882992 · Cited by 23
Epithelial–Mesenchymal Transition in Non-Small Cell Lung Cancer Management: Opportunities and Challenges
Ye, Y., Yu, S., Guo, T., Zhang, S., Shen, X., & Han, G. (2024) · Biomolecules · doi:10.3390/biom14121523 · Cited by 23
A review of avelumab in locally advanced and metastatic bladder cancer
Rao, A., & Patel, M. R. (2019) · Therapeutic Advances in Urology · doi:10.1177/1756287218823485 · Cited by 23
Research Progress on the Role of Regulatory T Cell in Tumor Microenvironment in the Treatment of Breast Cancer
Liu, J., Wang, X., Deng, Y., Yu, X., Wang, H., & Li, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.766248 · Cited by 23
Immunotherapy in cervical cancer: From the view of scientometric analysis and clinical trials
Xing, Y., Yasinjan, F., Du, Y., Geng, H., Zhang, Y., He, M., Guo, R., Yang, L., Cui, J., Mu, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1094437 · Cited by 22
Dual anti-PD-(L)1/TGF-β inhibitors in cancer immunotherapy – Updated
Karami, Z., Mortezaee, K., & Majidpoor, J. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110648 · Cited by 22
Degradation of intracellular TGF-β1 by PROTACs efficiently reverses M2 macrophage induced malignant pathological events
Feng, Y., Su, H., Li, Y., Luo, C., Xu, H., Wang, Y., Sun, H., Wan, G., Zhou, B., & Bu, X. (2020) · Chemical Communications · doi:10.1039/c9cc08391j · Cited by 22
Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management
Marté, J. L., Toney, N. J., Cordes, L. M., Schlom, J., Donahue, R. N., & Gulley, J. L. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001019 · Cited by 22
Self-citation
Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma
Strait, A. A., Woolaver, R. A., Hall, S. C., Young, C. D., Karam, S. D., Jimeno, A., Lan, Y., Raben, D., Wang, J. H., & Wang, J. H. (2021) · Communications Biology · doi:10.1038/s42003-021-02522-2 · Cited by 22
Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer
Rajan, A., Sater, H. A., Rahma, O. E., Agajanian, R., Lassoued, W., Marté, J. L., Tsai, Y.-T., Donahue, R. N., Lamping, E., Bailey, S., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008480 · Cited by 21
Self-citation
Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer
Qiu, M., Bai, Y., Wang, J., Gu, K., Yang, M., He, Y., Cheng, Y., Jin, Y., Liu, B., Wang, F., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02063-0 · Cited by 21
Bispecific anti-PD-1/LAG-3 antibodies for treatment of advanced or metastatic solid tumors: a patent evaluation of US2018326054
Cebada, J., Flores, A., Bandala, C., Ilizaliturri‐Flores, I., Villa‐Ruano, N., & Pérez-Santos, M. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1767071 · Cited by 21
Challenges and Opportunities in Targeting the Complex Pancreatic Tumor Microenvironment
Finan, J. M., Guo, Y., Goodyear, S. M., & Brody, J. R. (2024) · JCO oncology advances. · doi:10.1200/oa-24-00050 · Cited by 21
Knowing the tumour microenvironment to optimise immunotherapy
Merlano, M. C., Abbona, A., Denaro, N., & Garrone, O. (2019) · Acta Otorhinolaryngologica Italica · doi:10.14639/0392-100x-2481 · Cited by 19
Advances in immune therapies for the treatment of microsatellite instability‑high/deficient mismatch repair metastatic colorectal cancer (Review)
Choucair, K., Radford, M., Bansal, A. K., Park, R., & Saeed, A. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5254 · Cited by 19
Engineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and Challenges
Du, Y., & Xu, J. (2021) · Advanced Materials · doi:10.1002/adma.202103114 · Cited by 19
Therapeutic targeting of VEGF and/or TGF-β to enhance anti-PD-(L)1 therapy: The evidence from clinical trials
Li, L., Wen, Q., & Ding, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.905520 · Cited by 19
Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation
Santiago-Sánchez, G. S., Hodge, J. W., & Fabian, K. P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.993624 · Cited by 20
Molecular Pathways and Mechanisms of TGFβ in Cancer Therapy
Barcellos‐Hoff, M. H., & Gulley, J. L. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3750 · Cited by 21
Self-citation
The Role of Immune Checkpoint Inhibitors in Metastatic Pancreatic Cancer: Current State and Outlook
Tran, L. C., Özdemir, B. C., & Berger, M. D. (2023) · Pharmaceuticals · doi:10.3390/ph16101411 · Cited by 18
Immunotherapy in colorectal cancer: Statuses and strategies
Li, Y., Cheng, Z., Li, S., & Zhang, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e41354 · Cited by 24
Synergistic combination of oncolytic virotherapy with CAR T-cell therapy
Ajina, A., & Maher, J. F. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.06.015 · Cited by 20
Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF‐β and PD‐L1
Vugmeyster, Y., Wilkins, J. J., Köenig, A., Bawab, S. E., Dussault, I., Ojalvo, L. S., Banerjee, S. D., Klopp‐Schulze, L., & Khandelwal, A. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1776 · Cited by 20
Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development
Oliveira, L. J. D. C., Gongora, A. B. L., & Jardim, D. L. F. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00928-5 · Cited by 19
The Changing Landscape of Systemic Treatment for Cervical Cancer: Rationale for Inhibition of the TGF-β and PD-L1 Pathways
Birrer, M. J., Fujiwara, K., Oaknin, A., Randall, L. M., Ojalvo, L. S., Valencia, C., & Ray-Coquard, I. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.814169 · Cited by 20
Synergistic immunotherapy targeting cancer-associated anemia: prospects of a combination strategy
Yuan, T., Jia, Q., Zhu, B., Chen, D., & Long, H. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01145-w · Cited by 20
New techniques: a roadmap for the development of HCC immunotherapy
Jiang, D., Ma, X., Zhang, X., Cheng, B., Wang, R., Liu, Y., & Zhang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1121162 · Cited by 18
Population Pharmacokinetic Analysis of Bintrafusp Alfa in Different Cancer Types
Wilkins, J. J., Vugmeyster, Y., Dussault, I., Girard, P., & Khandelwal, A. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01018-0 · Cited by 18
Immunogenomic pan-cancer landscape reveals immune escape mechanisms and immunoediting histories
Mizuno, S., Yamaguchi, R., Hasegawa, T., Hayashi, S., Fujita, M., Zhang, F., Koh, Y., Lee, S.-Y., Yoon, S., Shimizu, E., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-95287-x · Cited by 21
Immune targeting of three independent suppressive pathways (TIGIT, PD-L1, TGFβ) provides significant antitumor efficacy in immune checkpoint resistant models
Franks, S. E., Fabian, K. P., Santiago-Sánchez, G. S., Wolfson, B., & Hodge, J. W. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2124666 · Cited by 17
New insights into fibrotic signaling in renal cell carcinoma
Chen, J., Yiu, W. H., Tang, P. M., & Tang, S. C. W. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1056964 · Cited by 18
Manipulating TGF-β signaling to optimize immunotherapy for cervical cancer
Yin, S., Cui, H., Qin, S., & Yu, S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115355 · Cited by 18
Bispecific antibodies for the treatment of breast cancer
Dillon, P. M., Tushir‐Singh, J., & Lum, L. G. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1922665 · Cited by 18
Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review
Reiter, F. P., Khaled, N. B., Ye, L., Zhang, C., Seidensticker, M., den Winkel, M. O., Denk, G., Geier, A., & Toni, E. N. D. (2021) · Digestive Diseases · doi:10.1159/000520095 · Cited by 17
The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma
Kou, L., Xie, X., Chen, X., Li, B., Li, J., & Li, Y. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03568-3 · Cited by 18
Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: a phase II trial
Yi, L., Pan, H., Ning, Z., Xu, L., Zhang, H., Peng, L., Liu, Y., Yang, Y., Si, W., Wang, Y., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02052-3 · Cited by 16
M7824: A promising new strategy to combat cancer immune evasion
Gatti-Mays, M. E., & Gulley, J. L. (2018) · Oncoscience · doi:10.18632/oncoscience.451 · Cited by 16
Self-citation
Bidirectional regulation between tumor cell-intrinsic PD-L1 and TGF-β1 in epithelial-to-mesenchymal transition in melanoma
Li, Z., Wang, F., Dang, J., Cheng, F., & Zheng, F. (2022) · Translational Cancer Research · doi:10.21037/tcr-22-292 · Cited by 14
Efficacy, safety, and correlative biomarkers of bintrafusp alfa in recurrent or metastatic nasopharyngeal cancer patients: a phase II clinical trial
Chiang, C., Lam, T., Li, J. C. B., Chan, S.-K., Helali, A. E., Lee, Y. Y. P., Law, L. H. T., Zheng, D., Lo, A. W. I., Kam, N., et al. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100898 · Cited by 15
Epigenetic regulation of TGF-β pathway and its role in radiation response
Ding, Y., Zhou, G., & Hu, W. (2024) · International Journal of Radiation Biology · doi:10.1080/09553002.2024.2327395 · Cited by 15
The evolving landscape of biomarkers for systemic therapy in advanced hepatocellular carcinoma
Guo, X., Zhao, Z., Zhu, L., Liu, S., Zhou, L., Wu, F., Fang, S., Chen, M., Zheng, L., & Ji, J. (2025) · Biomarker Research · doi:10.1186/s40364-025-00774-2 · Cited by 17
Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF-β for Anticancer Immunotherapy
Wu, Z.-H., Li, N., Gao, Z., Chen, G., Nie, L., Zhou, Y., Jiang, M.-Z., Chen, Y., Chen, J., Mei, X.-F., et al. (2022) · Cancers · doi:10.3390/cancers14194964 · Cited by 13
RETRACTED: Dual targeting of TGF-β and PD-L1 inhibits tumor growth in TGF-β/PD-L1-driven colorectal carcinoma
Khalili‐Tanha, G., Fiuji, H., Gharib, M., Moghbeli, M., Khalili‐Tanha, N., Rahmani, F., Shakour, N., Maftooh, M., Hassanian, S. M., Asgharzadeh, F., et al. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121865 · Cited by 16
Retracted
An innovative antibody fusion protein targeting PD-L1, VEGF and TGF-β with enhanced antitumor efficacies
Fan, W., Chen, Y., Zhou, Z., Duan, W., Yang, C., Sheng, S., Wang, Y., Wei, X., Liu, Y., & Huang, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111698 · Cited by 14
Radiation-primed TGF-β trapping by engineered extracellular vesicles for targeted glioblastoma therapy
Liang, R., Lu, H., Zhu, H., Liang, G., Zhang, J., Gao, J., & Tian, T. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.05.022 · Cited by 16
Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data
Song, Z., Zou, K., & Zou, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1045481 · Cited by 15
PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancer
Floudas, C., Goswami, M., Donahue, R. N., Strauss, J., Pastor, D. M., Redman, J., Brownell, I., Turkbey, E., Steinberg, S., Cordes, L., et al. (2025) · Cancer Immunology and Immunotherapy · doi:10.1007/s00262-025-04009-z · Cited by 13
Self-citation
From immune checkpoints to therapies: understanding immune checkpoint regulation and the influence of natural products and traditional medicine on immune checkpoint and immunotherapy in lung cancer
Zhou, Y., Wang, F., Li, G., Xu, J., Zhang, J., Gullen, E. A., Yang, J., & Wang, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340307 · Cited by 13
Targeted Therapies in Advanced and Metastatic Urothelial Carcinoma
Katims, A. B., Reisz, P., Nogueira, L., Truong, H., Lenis, A., Pietzak, E., Kim, K., & Coleman, J. (2022) · Cancers · doi:10.3390/cancers14215431 · Cited by 13
Heterogeneity and plasticity of cancer-associated fibroblasts
Pramod, S., Lavon, H., Scherz‐Shouval, R., & Sherman, M. H. (2026) · Nature Cancer · doi:10.1038/s43018-026-01146-x · Cited by 14
Emerging target discovery and drug repurposing opportunities in chordoma
Freed, D. M., Sommer, J., & Punturi, N. B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1009193 · Cited by 11
Roles of tissue-resident immune cells in immunotherapy of non-small cell lung cancer
Tang, R., Wang, H., & Tang, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1332814 · Cited by 13
Cancer progression and tumor hypercoagulability: a platelet perspective
Zhang, Y., Zeng, J., Bao, S., Zhang, B., Li, X., Wang, H., Cheng, Y., Zhang, H., Zu, L., Xu, X. N., et al. (2024) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-024-02993-0 · Cited by 12
Gadoxetic Acid-Enhanced Magnetic Resonance Imaging Features Can Predict Immune-Excluded Phenotype of Hepatocellular Carcinoma
Ueshima, E., Sofue, K., Kodama, T., Yamamoto, S., Komatsu, M., Komatsu, S., Ishihara, N., Umeno, A., Yamaguchi, T., Hori, M., et al. (2024) · Liver Cancer · doi:10.1159/000542099 · Cited by 12
SMAD-oncoprotein interplay: Potential determining factors in targeted therapies
Li, X., & Feng, X. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114155 · Cited by 13
Molecular-targeted therapy toward precision medicine for gastrointestinal caner: Current progress and challenges
Matsuoka, T., & Yashiro, M. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i5.366 · Cited by 13
Heterogeneity in Pancreatic Cancer Fibroblasts—TGFβ as a Master Regulator?
Watt, D. M., & Morton, J. P. (2021) · Cancers · doi:10.3390/cancers13194984 · Cited by 12
NHS-IL12 and bintrafusp alfa combination therapy enhances antitumor activity in preclinical cancer models
Xu, C., Marelli, B., Qi, J., Qin, G., Yu, H., Wang, H., Jenkins, M. H., Lo, K.-M., & Lan, Y. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101322 · Cited by 12
Insights into immuno-oncology drug development landscape with focus on bone metastasis
Kähkönen, T. E., Halleen, J. M., MacRitchie, G., Andersson, R. M., & Bernoulli, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1121878 · Cited by 12
The clinical terrain of immunotherapies in heterogeneous pancreatic cancer: unravelling challenges and opportunities
Herpels, M., Ishihara, J., & Sadanandam, A. (2023) · The Journal of Pathology · doi:10.1002/path.6171 · Cited by 11
Revealing profile of cancer-educated platelets and their factors to foster immunotherapy development
Trivanović, D. I., Mojsilović, S. B., Bogosavljević, N., Jurišić, V., & Jauković, A. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101871 · Cited by 11
Combination Therapies for HPV-Associated Malignancies.
Rumfield, C. S., Schlom, J., & Jochéms, C. (2021) · PubMed · Cited by 10
Self-citation
Deciphering molecular mechanisms of metastasis: novel insights into targets and therapeutics
Kalita, B., & Coumar, M. S. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00611-2 · Cited by 11
Receptor-Mediated Redox Imbalance: An Emerging Clinical Avenue against Aggressive Cancers
Dai, X., Thompson, E. W., & Ostrikov, K. (2022) · Biomolecules · doi:10.3390/biom12121880 · Cited by 11
Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma
Jang, A., Lichterman, J. N., Zhong, J. Y., Shoag, J. E., Garcia, J. A., Zhang, T., & Barata, P. C. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2276629 · Cited by 12
Targeting the immune milieu in gastrointestinal cancers
Turkes, F., Mencel, J., & Starling, N. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01710-x · Cited by 11
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study
Baranda, J. C., Robbrecht, D. G. J., Sullivan, R. J., Doger, B., Santoro, A., Barve, M. A., Grob, J., Bechter, O. E., Vieito, M., de Miguel, M. J., et al. (2024) · Clinical and Translational Science · doi:10.1111/cts.13854 · Cited by 10
Roles of TGF-β in cancer hallmarks and emerging onco-therapeutic design
Dai, X., Hua, D., & Lu, X. (2022) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2022.37 · Cited by 10
Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists
Cirella, A., Bolaños, E., Luri‐Rey, C., Trani, C. A. D., Olivera, I., Gomis, G., Glez‐Vaz, J., Pinci, B., Garasa, S., Sánchez‐Gregorio, S., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.07.026 · Cited by 10
Exploring natural killer cell immunology as a therapeutic strategy in lung cancer
Hess, J. B., Sutherland, K. D., & Best, S. A. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-765 · Cited by 10
Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer
Cheng, Y., Li, H., Zhang, L., Liu, J., Yang, C., & Zhang, S. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001560 · Cited by 10
Transforming growth factor-β micro-environment mediated immune cell functions in cervical cancer
Gnanagurusamy, J., Krishnamoorthy, S., & Muthusami, S. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112837 · Cited by 9
Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors
Hernando‐Calvo, A., Carvajal, R. D., Paik, P. K., Morris, V. K., Zandberg, D. P., Kaczmar, J. M., Bohr, D. N., Reiners, R. D., Gharakhani, E., Salazar, R. L., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0100 · Cited by 9
TGF-β-mediated suppression of NK cell function and targeting strategies in tumor immunotherapy
Wang, B., & Bi, J. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105141 · Cited by 10
Safety and clinical efficacy of immune checkpoint inhibitors in advanced gastric cancer in the real world
Hao, W., Liu, W., Chang, R., Yang, M., Xin, K., Liu, J., Wang, Y., Ren, M., Xie, J., & Yang, Y. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05703-8 · Cited by 9
Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic
Donahue, R. N., Marté, J. L., Goswami, M., Toney, N. J., Tsai, Y.-T., Gulley, J. L., & Schlom, J. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002087 · Cited by 9
Self-citation
The potential application of stroma modulation in targeting tumor cells: Focus on pancreatic cancer and breast cancer models
Roscigno, G., Jacobs, S., Toledo, B., Borea, R., Russo, G., Pepe, F., Serrano, M. J., Calabrò, V., Troncone, G., Giovannoni, R., et al. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.05.003 · Cited by 9
Exploring the multifaceted role of TGF-β signaling in diabetic complications
Behl, T., Gupta, A., Sehgal, A., Singh, S., Sharma, N., Garg, M., Bhatia, S., Al‐Harrasi, A., Aleya, L., & BUNGAU, S. G. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-19499-y · Cited by 9
An overview of up-and-coming immune checkpoint inhibitors for pancreatic cancer
Mahadevia, H. J., Usón, P. L. S., Wang, J., Borad, M. J., & Babiker, H. M. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2304125 · Cited by 8

Authors: Strauss, J., Heery, C. R., Schlom, J., Madan, R. A., Cao, L., Kang, Z., Lamping, E., Marté, J. L., Donahue, R. N., Grenga, I., Cordes, L., Christensen, O., Mahnke, L., Helwig, C., & Gulley, J. L.
Affiliations: National Institutes of Health (US)
7EMD Serono, Billerica, Massachusetts.
Merck KGaA, Darmstadt (Germany) (DE)
Corresponding author: Gulley, James L.
ORCID: Strauss, Julius
Schlom, Jeffrey
Madan, Ravi A.
Cao, Liang
Kang, Zhigang
Marté, Jennifer L.
Donahue, Renee N.
Cordes, Lisa
Helwig, Christoph
Gulley, James L.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2018-03-14
Volume: 24
Issue: 6
Pages: 1287-1295
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-17-2653
PMC: PMC7985967
OpenAlex: W2781947653
Cited by: 406
References: 35
Citations by year: 2026: 22 · 2025: 29 · 2024: 48 · 2023: 40 · 2022: 81 · 2021: 73 · 2020: 64 · 2019: 26 · 2018: 20
FWCI: 17.20
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (HHSN261200800001C)
National Cancer Institute (HHSN261200800001E), ZIABC010945)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: bifunctional fusion protein, PD-L1, TGF-β trap, TGF-β1, TGF-beta2, TGF-beta3, advanced solid tumors, maximum tolerated dose, safety, pharmacokinetics, immunogenicity, cervical cancer, pancreatic cancer, anal cancer, carcinoid tumor, dose escalation
MeSH terms: Antineoplastic Agents, Immunological, Adult, Aged, Combined Modality Therapy, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Neoplasms, Transforming Growth Factor beta, Treatment Outcome, Antibodies, Bispecific, Retreatment, Molecular Targeted Therapy, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks